We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Anyone shed any light on where the hell all of my £15k investment has gone?
News just issued for XEN.
Entry into CAR T space positions company to drive significant momentum over the course of 2019 advancing XCART platform technology
– XCART initially being developed to target B-cell lymphomas and has the potential to address multiple tumor types with an initial global market opportunity in Non-Hodgkin Lymphoma of over $5 billion annually
“We expect 2019 to be a transformative year for Xenetic. With the anticipated closing of our acquisition
of XCART, our differentiated CAR T platform technology, on track for this quarter, I believe Xenetic will be
well positioned to drive momentum in the innovation and development of new oncology therapeutics
where there remains significant unmet need,” commented Jeffrey Eisenberg, Chief Executive Officer of
Xenetic. “We plan to focus our R&D efforts initially on leveraging the XCART platform to develop cell-
based therapeutics for the treatment of B-cell Non-Hodgkin lymphomas. All of this marks a very important
moment in the evolution of Xenetic, and I firmly believe the Company can become a significant player in
the oncology space with this potentially transformative technology platform, providing therapeutic
solutions for physicians and individuals fighting cancer and their families as well as driving value for our
shareholders.”
RNS 5.4.19
The gross proceeds to Xenetic from the registered direct offering are expected
to be approximately $3.1 million before deducting placement agent fees and
other offering expenses. The offering is expected to close on or about March
7, 2019, subject to the satisfaction of customary closing conditions.
RNS 4.3.19
Xenetic announced today its agreement to acquire the novel CAR T ("Chimeric Antigen
Receptor T Cell") platform technology, called "XCART," a proximity-based
screening platform capable of identifying CAR constructs that can target
patient-specific tumor neoantigens, with a demonstrated proof of mechanism in
B-cell Non-Hodgkin lymphomas. The XCART technology, developed by The Scripps
Research Institute ("Scripps") in collaboration with the Shemyakin-Ovchinnikov
Institute of Bioorganic Chemistry, is believed to have the potential to
significantly enhance the safety and efficacy of cell therapy for B-cell
lymphomas by generating patient- and tumor-specific CAR T cells. The
acquisition is subject to conditions typical for a transaction of this kind,
including appropriate stockholder approvals, and is expected to close in the
first half of 2019.
"This acquisition is a transformative step in the strategic evolution of
Xenetic," commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic.
Funding now from placings rather than 'partners' !
Seems way to quiet, especially on here.
Does anyone know whether we have anything coming up soon to look forward too?
Been here for near on 10 years now and still every time we seem to go over the projected dates / periods for trial results and news etc.
Frustrating.....
'Dad why is my sister named Teresa?'
'Because your mum loves Easter and Teresa is an anagram of Easter''
'Thanks Dad'
'No problem Alan'
Have held a common stock certificate since they transferred across the water.Can anyone on the board give any contact info as no joy with xbio HQ Thanks in advance
What the hell is going on!!!
https://seekingalpha.com/news/3366049-xenetic-biosciences-doubles-heavy-volume
It's ip100% today but there s no news on the clinical trial(s).
We seem to have some activity recently - any one offer any insight as to why?
A message from Seeking Alpha healthcare that xbio is 164% up.
And the rest. It will either continue or go back to 1.50. No news again
Up 34% Today.
The only info about xbio is their corporate presentation of May 2018. It's here https://www.xeneticbio.com/news-media/presentations if anyone hasn't seen it.
http://allamed.ru/administaciya-po-kontrolyu-za-prodovolestvennimi-i-farmacevtic.html
Para - is that Russian one even running? I think the whole thing is a joke now. Wonder will we ever see close to what we paid. If the results are good it could be 100 dollars but knowing our luck it will come in and boom
The clinical trial sponsored by XBIO is estimated to complete in 2021. See: https://www.clinicaltrials.gov/ct2/show/NCT03077698?term=sodium+cridanimod&rank=2 Pharmasyntez is doing the same trial. Expected to finish phase 2 in July 2018. See; https://www.clinicaltrials.gov/ct2/show/record/NCT02064725?term=sodium+cridanimod&rank=1
Takeda agrees to buy Shire in £46bn deal http://www.bbc.co.uk/news/business-44038049
Seems they trying to keep somethings secret or they just too useless to get filing on time
So what is the amended annual report for? Just to explain the exaggerated salaries of the board?
On February 27, 2017, Pharmsynthez acquired 100% of SynBio. As a result, SynBio’s ownership stake is reflected as part of Pharmsynthez’ share ownership. Pharmsynthez, directly and indirectly through SynBio, has a share ownership in the Company of approximately 61.5% of the total issued common stock as of December 31, 2017.
SynBio applied for and received regulatory approval to commence ErepoXen Phase II(b)/III human clinical trials in Russia and is currently recruiting patients. SynBio has indicated that it intends to commence the commercialization and marketing stages of ErepoXen in the Russian and CIS markets subject to approval in such markets.
Have you got any info on SynBio's clinical trial protocol number, because I cannot find Synbio in any trial in Russia. I have found a Pharmasyntez clinical trial which is Virexxa (XBIO -101) See: https://clinicaltrials.gov/ct2/show/NCT02064725 . The clinical study sponsor is Kevelt AS. The study ends in July 2018. Synbio's website doesn't work.